

Predictors of Variation in Serum IGF1 and IGFBP3 Levels in Healthy African American and White Men

Cathrine Hoyo, PhD; Janet Grubber, MSPH; Wendy Demark-Wahnefried, PhD; Bruce Lobaugh, PhD; Amy S. Jeffreys, MStat; Steven C. Grambow, PhD; Jeffrey R. Marks, PhD; Temitope O. Keku, PhD; Phillip J. Walther, MD, PhD; Joellen M. Schildkraut, PhD

Financial Support: This work was supported by K01CA104517, 5U21-CA78157, and Department of Veterans Affairs (CSP 708D).

Disclosure: The views expressed in this article are those of the authors and do not necessarily represent the view of the Department of Veterans Affairs.

Background: Individual variation in circulating insulinlike growth factor-1 (IGF1) and its major binding protein, insulinlike growth factor binding protein-3 (IGFBP3), have been etiologically linked to several chronic diseases, including some cancers. Factors associated with variation in circulating levels of these peptide hormones remain unclear.

Methods: Multiple linear regression models were used to determine the extent to which sociodemographic characteristics, lifestyle factors, personal and family history of chronic disease, and common genetic variants, the (CA)_n repeat polymorphism in the IGF1 promoter and the IGFBP3-202 A/C polymorphism (rs2854744) predict variation in IGF1 or IGFBP3 serum levels in 33 otherwise healthy African American and 37 white males recruited from Durham Veterans Administration Medical Center.

Results: Predictors of serum IGF1, IGFBP3, and the IGF1:IGFBP3 molar ratio varied by race. In African Americans, 17% and 28% of the variation in serum IGF1 and the IGF1:IGFBP3 molar ratio, were explained by cigarette smoking and carrying the IGF1 (CA)₁₉ repeat allele, respectively. Not carrying at least 1 IGF1 (CA)₁₉ repeat allele and a high body mass index explained 8% and 14%, respectively, of the variation in IGFBP3 levels. These factors did not predict variation of these peptides in whites.

Conclusion: If successfully replicated in larger studies, these findings would add to recent evidence, suggesting known genetic and lifestyle chronic disease risk factors influence IGF1 and IGFBP3 circulating levels differently in African Americans and whites.

Keywords: insulin ■ race/ethnicity

J Natl Med Assoc. 2009;101:711-716

Author Affiliations: Department of Community and Family Medicine (Drs Hoyo and Schildkraut), Department of Surgery, Division of Urology (Drs Demark-Wahnefried and Walther), Department of Obstetrics and Gynecology, Division of Oncology (Dr Lobaugh), Department of Biostatistics and Bioinformatics (Dr Grambow), Department of Experimental Surgery (Dr Marks), School of Nursing (Dr Demark-Wahnefried), Duke University Medical Center, Durham, North Carolina; Cancer Detection, Prevention and Control Program, Duke University Comprehensive Cancer Center, Durham, North Carolina (Drs Hoyo and Schildkraut, Ms Grubber); Epidemiologic Research and Information Center, Veterans Administration Medical Center, Durham, North Carolina (Dr Grambow, Ms Jeffreys); Department of Medicine, Division of Gastroenterology, University of North Carolina, Chapel Hill, North Carolina (Dr Keku).

Corresponding Author: Cathrine Hoyo PhD, Department of Community and Family Medicine, Duke University Medical Center, Box 2914, Durham, NC 27710 (hoyo0001@mc.duke.edu).

INTRODUCTION

Insulinlike growth factor-1 (IGF1) is a potent broad-spectrum mitogenic growth factor with antiapoptotic properties. Elevated circulating concentrations of IGF1 have been etiologically linked to several chronic diseases, including type 2 diabetes;¹ cardiovascular diseases;^{2,3} and cancers of the breast,⁴⁻⁶ colon,^{7,8} and prostate.^{6,9-18} Circulating IGF1 levels are modulated by the formation of the ternary complex that binds to IGFBP3 and/or IGFBP5 and an acid labile subunit (ALS) too large to pass through the endothelial wall.^{6,19} Independently of regulating the availability of IGF1 in circulation, IGFBP3 also induces apoptosis.²⁰ Lower circulating concentrations of IGFBP3 have also been linked to increased risk of several malignancies.^{6,9,11,13,17,21-23}

For reasons that are still poorly understood, there is considerable interindividual variation in serum concentrations of both IGF1 and IGFBP3. Whereas age-related declines in IGF1 and IGFBP3 serum levels have been repeatedly demonstrated in men and women,²⁴⁻²⁷ data on the utility of demographic and lifestyle factors such as cigarette smoking, sex,^{24,26,28,29} race,³⁰⁻³³ and body mass index (BMI), to predict variation in these peptides are inconsistent. In addition, although common nonsynonymous genetic variants in *IGF1* and *IGFBP3* have been

evaluated in relation to chronic disease risk in many case-control studies because of their association with circulating protein products of these genes, the capacity of these variants to predict circulating levels also remains unclear.^{27,34-36} The availability of both genetic variant and lifestyle data in otherwise healthy African American and white men provided the impetus to evaluate the extent to which together these factors predict IGF1 and IGFBP3 serum concentrations in healthy men.

METHODS

Study Participants

Participants included in these analyses served as healthy controls for a hospital-based, case-control study of prostate cancer conducted at the Durham Veterans Administration Medical Center (DVAMC). Methods of participant accrual and data collection have been detailed elsewhere.^{37,38} Briefly, as part of a hospital-based, case-control study, 181 consecutive hospital controls aged 40 to 75 years were identified and matched to cases by race and age, between January 1999 and July 2001, at the DVAMC, North Carolina. Of the 181 controls identified, 96 were enrolled, 2 withdrew, and 2 were lost between identification and interview—a response rate of 53%. We further excluded 26 men for whom genotype or other covariate data were unavailable such that 70 participants were available for these analyses, 33 of them African American.

Data Collection

On scheduled visits to the DVAMC, a trained nurse conducted in-person interviews using a standardized questionnaire to obtain data on sociodemographic and lifestyle factors, as well as family and personal history of several chronic diseases, including prostate cancer, other cancers, and diabetes. Following the interview, 30 mL of peripheral blood were collected in 10-mL EDTA-treated tubes. Serum and buffy coat were isolated within 2 hours of collection and stored in a -70°C freezer. PureGene system reagents (Gentra, Minneapolis, Minnesota) were used to extract and resuspend genomic DNA according to manufacturer's protocol.

Genotyping

Detailed methods for ascertaining polymorphic variants also have been previously described. To determine the repeat length of the *IGF1* (CA)_n microsatellite, located 1 kb upstream of the gene's transcription start site, polymerase chain reaction was performed using previously published unlabelled primers obtained from Integrated DNA Technologies (Coralville, Iowa). The forward and reverse primers used were 5'-GCT AGC CAG CTG GTG TTA TT-3' and 5'-ACC ACT CTG GGA GAA GGG TA-3', respectively. The *IGFBP3* single nucleotide polymorphism (-202 (A/C) (rs2854744) was analyzed according to Deal et al.³⁴ The forward and

reverse primers used were 5'-CCA CGA GGT ACA CAC GAA TG-3' and 5'-AGC CGC AGT GCT CGC ATC TGG-3', respectively.

Serum Measurement of IGF1 and IGFBP3

We measured IGF1 and IGFBP3 concentrations at the time of data collection. Measurements were according to manufacturer's protocol, in duplicate using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Diagnostic Systems Laboratories, Webster, Texas). Each assay batch included positive controls and masked samples derived from pooled serum specimens. If the 2 measurements were widely divergent (an infrequent occurrence), assays were repeated up to 2 additional times. The average of 2 measurements for each analyte was used for data analysis. The sensitivities of the assay used were as follows: IGF1 = 0.03 ng/mL and IGFBP3 = 0.04 ng/mL. In addition to quantifying IGF1 and IGFBP3 concentrations, we also estimated the molar ratio of IGF1/IGFBP3 as the quantity (IGF1 in ng/mL \times 0.130) / (IGFBP3 ng/mL \times 0.036), where the constants are the molecular weights of the respective polypeptide. The molar ratio is often used as a surrogate for the more relevant unbound IGF1.^{24,31}

Statistical Analyses

Age-adjusted means and standard deviations for IGF1, IGFBP3 and the IGF1:IGFBP3 molar ratio were computed for the overall sample and in the presence and absence of each predictor for African Americans and whites together as well as separately by race. Predictors were dichotomized as follows: age (<60 years vs \geq 60 years), education (graduated from high school vs not graduated from high school), smoking (100 cigarettes in a lifetime vs never smoked 100 cigarettes in a lifetime), diabetic vs not diabetic, normal BMI (BMI <25 kg/m²) vs overweight (BMI = 25-<30 kg/m²) vs obese (BMI \geq 30 kg/m²), family history of prostate cancer in father or brother vs none, homozygote and heterozygote carriers vs noncarrier of the *IGF1* (CA)₁₉ repeat allele, homozygote and heterozygote carriers vs noncarrier of the *IGFBP3* -202bp A-allele. Multiple regression models using PROC REG in SAS (Cary, North Carolina) were used to identify factors independently associated with IGF1 and IGFBP3 levels. Using backward selection strategies, β coefficients and partial r^2 for each factor in the final model were also computed to determine the proportion of variation contributed by each factor. Although age did not independently predict a decrease in total IGF1 or IGFBP3 concentration, it was retained in all models since it is a known determinant of these peptides. Statistical analyses were conducted using SAS version 9.1 (SAS, Cary, North Carolina).

RESULTS

The distribution and age-adjusted means and 95% confidence intervals (CIs) for serum IGF1, IGFBP3, and

IGF1:IGFBP3 molar ratios of 33 African American and 37 white men are presented in Table 1. Among all participants, serum levels of IGF1, IGFBP3, and IGF1:IGFBP3 molar ratio did not vary significantly by diabetes, BMI, family history of prostate cancer, or carrying the A at -202bp of the *IGFBP3* genotypes. However, African American noncarriers of the *IGF1 (CA)₁₉* repeat had lower IGF1 levels (117; 95% CI, 94-140 ng/mL) and

lower IGF1:IGFBP3 molar ratio (0.21; 95% CI, 0.17-0.25) compared to whites. Also, cigarette smoking in African Americans had somewhat lower IGF1:IGFBP3 molar ratio and IGF1 levels compared to white smokers (IGF1 mean, 114 ng/mL; 95% CI, 97-130 for African Americans vs mean, 131 ng/mL; 95% CI, 109-153 for whites; IGFBP1:IGFBP3 molar ratio 0.22 and 0.27 for African Americans and white men, respectively). African

Table 1. Age-Adjusted Mean (ng/mL) Serum IGF1, IGFBP3, and IGF1:IGFBP3 Molar Ratio Among Healthy African American and White Men

Characteristic	Overall (N = 70)		African Americans (N = 33)		Whites (N = 37)	
Never smoked 100 cigarettes, n (%)	15	(21.4)	10	(30.3)	5	(13.5)
IGF1, mean (95% CI)	132	(104-159)	151	(126-176)	102	(46-158)
IGFBP3, mean (95% CI)	1799	(1393-2205)	2037	(1665-2410)	1438	(565-2311)
IGF1:IGFBP3, mean (95% CI)	0.28	(0.24-0.32)	0.28	(0.24-0.33)	0.27	(0.19-0.36)
Ever smoked 100 cigarettes, n (%)	55	(78.6)	23	(69.7)	32	(86.5)
IGF1, mean (95% CI)	125	(110-139)	114	(97-130)	131	(109-153)
IGFBP3, mean (95% CI)	1874	(1623-2086)	1874	(1629-2119)	1856	(1518-2195)
IGF1:IGFBP3, mean (95% CI)	0.25	(0.24-0.29)	0.22	(0.19-0.25)	0.27	(0.24-0.30)
BMI <25 kg/m ² , n (%)	11	(15.7)	5	(15.2)	6	(16.2)
IGF1, mean (95% CI)	121	(89-153)	121	(82-159)	131	(76-187)
IGFBP3, mean (95% CI)	1810	(1338-2282)	1837	(1370-2305)	1916	(1039-2794)
IGF1:IGFBP3, mean (95% CI)	0.24	(0.19-0.29)	0.23	(0.16-0.30)	0.24	(0.15-0.32)
BMI 25-<30 kg/m ² , n (%)	27	(38.6)	11	(33.3)	16	(43.2)
IGF1, mean (95% CI)	114	(94-134)	113	(87-139)	111	(80-143)
IGFBP3, mean (95% CI)	1627	(1332-1922)	1561	(1247-1876)	1632	(1138-2127)
IGF1:IGFBP3, mean (95% CI)	0.27	(0.24-0.30)	0.26	(0.22-0.31)	0.28	(0.23-0.32)
BMI ≥30 kg/m ² , n (%)	32	(45.7)	17	(51.5)	15	(40.5)
IGF1, mean (95% CI)	138	(120-157)	135	(114-156)	142	(110-174)
IGFBP3, mean (95% CI)	2069	(1799-2340)	2183	(1931-2435)	1932	(1429-2434)
IGF1:IGFBP3, mean (95% CI)	0.25	(0.22-0.28)	0.23	(0.19-0.27)	0.28	(0.23-0.32)
Noncarriers of the IGF1 (CA) ₁₉ genotype, n (%)	19	(27.1)	14	(42.4)	5	(13.5)
IGF1, mean (95% CI)	119	(95-144)	117	(94-140)	136	(79-193)
IGFBP3, mean (95% CI)	1921	(1558-2284)	2084	(1775-2393)	1585	(711-2460)
IGF1:IGFBP3, mean (95% CI)	0.23	(0.19-0.27)	0.21	(0.17-0.25)	0.29	(0.21-0.37)
Heterozygous for the (CA) ₁₉ genotype, n (%)	28	(40.0)	14	(42.4)	14	(37.8)
IGF1, mean (95% CI)	129	(109-149)	133	(110-156)	124	(90-158)
IGFBP3, mean (95% CI)	1805	(1506-2105)	1872	(1563-2181)	1720	(1195-2244)
IGF1:IGFBP3, mean (95% CI)	0.27	(0.24-0.30)	0.26	(0.22-0.30)	0.28	(0.23-0.33)
Homozygous for the (CA) ₁₉ genotype, n (%)	23	(32.9)	5	(15.2)	18	(48.6)
IGF1, mean (95% CI)	128	(106-151)	126	(87-165)	127	(97-157)
IGFBP3, mean (95% CI)	1870	(1539-2202)	1619	(1102-2136)	1922	(1463-2381)
IGF1:IGFBP3, mean (95% CI)	0.26	(0.23-0.29)	0.28	(0.22-0.35)	0.25	(0.21-0.30)
IGFBP3 -202bp AA genotype	16	22.9	10	30.3	6	16.2
IGF1, mean (95% CI)	125	(99-152)	137	(110-164)	114	(58-170)
IGFBP3, mean (95% CI)	1642	(1255-2029)	1725	(1365-2086)	1600	(744-2456)
IGF1:IGFBP3, mean (95% CI)	0.27	(0.23-0.31)	0.29	(0.24-0.33)	0.24	(0.16-0.32)
IGFBP3 -202bp AC genotype	31	44.3	15	45.5	16	43.2
IGF1, mean (95% CI)	125	(106-144)	115	(92-137)	133	(101-165)
IGFBP3, mean (95% CI)	2062	(1785-2338)	2124	(1830-2419)	1988	(1503-2472)
IGF1:IGFBP3, mean (95% CI)	0.23	(0.20-0.26)	0.20	(0.17-0.24)	0.26	(0.21-0.30)
IGFBP3 -202bp CC genotype	23	32.9	8	24.2	15	40.5
IGF1, mean (95% CI)	129	(107-151)	130	(99-161)	126	(93-159)
IGFBP3, mean (95% CI)	1735	(1413-2057)	1795	(1388-2203)	1679	(1174-2184)
IGF1:IGFBP3, mean (95% CI)	0.28	(0.25-0.31)	0.26	(0.21-0.31)	0.29	(0.24-0.34)

American men with a high BMI had lower levels of IGF1 and IGF1:IGFBP3 molar ratio compared to whites.

Similar to previous reports,^{39,40} in race-stratified analyses multivariable regression models fit to identify significant predictors of serum concentrations of IGF1, and IGF1/IGFBP-3 molar ratio (Table 2), we found that age, circulating IGF1 and IGFBP3 were inversely related, predicting most of the variation in serum IGF1 and IGFBP3. In contrast, no other factors were significant predictors of circulating IGF1 or IGFBP3 levels in white men. However, in African American men, the 2 independent predictors of serum IGF1 levels were a history of cigarette smoking and carrying the *IGF1 (CA)₁₉* repeat allele. These 2 factors explained 17% of the individual variation in IGF1 and 28% of the variation in IGF1:IGFBP3 molar ratio, whereas, a large BMI and being a noncarrier of the *IGF1 (CA)₁₉* repeat explained 22% of the variation in circulating IGFBP3. Factors previously reported to predict IGF1 and IGFBP3, including a high-fat diet, alcohol use, diabetes, carrying the *IGFBP3 – 202 C*-allele, and a large waist circumference, did not independently predict serum IGF1 or IGFBP3 in African Americans or whites.

DISCUSSION

In this study we found that the effect of lifestyle factors, including cigarette smoking and a large BMI as well as carrying at least 1 *IGF1 (CA)₁₉* repeat allele predicted serum IGF1 and IGFBP3 in African Americans

but not whites, explaining 28% of the variation in IGF1:IGFBP3 molar ratio; 17% of the variation in serum IGF1 and 22% of the variation in serum IGFBP3. These findings contrast with those of other studies where no racial differences in the effect of genetic or lifestyle factors were found.³⁹⁻⁴¹ Although IGF1 and IGFBP3 proteins have been evaluated extensively in different race/ethnic groups, to our knowledge, this is the first study to demonstrate the utility of this common genetic variant together with lifestyle factors to predict serum IGF1 and IGFBP3 in otherwise healthy African American men, suggesting that race/ethnicity-dependent mechanisms are important. If confirmed, these findings may explain, in part, inconsistent findings among studies evaluating associations between established risk factors and chronic disease endpoints where race/ethnicity data are not taken into account.

The finding that carrying at least 1 copy of the *IGF1 (CA)₁₉* dinucleotide repeat allele predicted IGF1 and IGFBP3 levels in African Americans, but not in whites contrasts with at least 3 of the 5 studies that have evaluated the association between carrying the *IGF1(CA)₁₉* allele, and IGF1 or IGFBP3 levels^{24,31,35,36} where lower levels of IGF1 were found among predominantly white individuals carrying this common genetic variant. In Japanese²⁷ and British⁴² studies, no association between carrying the *IGF1 (CA)₁₉* repeat allele and IGF1 levels was found, although increased IGFBP3 levels were noted by others.²⁷ These studies had few or no African

Table 2. Multivariable Linear Regression Models for Serum Levels of Insulinlike Growth Factors by Race

	African Americans			Whites		
	β (SE)	P Value (Model)	r ² (Model)	β (SE)	P Value (Model)	r ² (Model)
		Variable	Partial		Variable	Partial
IGF1		(.0005)	(0.50)		(<.0001)	(0.68)
Age at interview	-0.92 (0.65)	.17	0.09	-1.111 (1.203)	.36	0.07
Ever smoked 100 cigarettes (yes/no)	-29.60 (12.69)	.03	0.15	-	NS	-
<i>IGF1 (CA)₁₉</i> repeat (carrier/noncarrier)	24.07 (12.03)	.06	0.02	-	NS	-
IGFBP3 serum level	0.039 (0.011)	.001	0.23	0.052 (0.007)	<.0001	0.61
IGFBP3		(.0006)	(0.49)		(<.0001)	(0.67)
Age at interview	-0.524 (8.89)	.95	0.03	-0.299 (18.78)	.99	0.05
BMI (kg/m ²)	34.45 (13.77)	.02	0.14	-	NS	-
<i>IGF1 (CA)₁₉</i> repeat (carrier/noncarrier)	-409.1 (155.5)	.01	0.08	-	NS	-
IGF1 serum level	6.94 (1.90)	.001	0.24	12.49 (1.55)	<.0001	0.62
IGF1:IGFBP3 molar ratio		(.02)	(0.29)		(.82)	(0.001)
Age at interview	-0.001 (0.001)	.59	0.01	0.001 (0.003)	.82	0.001
Ever smoked 100 cigarettes (yes/no)	-0.055 (0.024)	.03	0.13	-	NS	-
<i>IGF1 (CA)₁₉</i> repeat (carrier/noncarrier)	0.055 (0.023)	.02	0.15	-	NS	-

Abbreviation: NS, not significant in the model.

Americans. In a large American multiethnic study, no race/ethnic differences in the relationship between carrying the *IGFBP3 -202A* and serum IGFBP3 or IGF1 were noted.⁴⁰

Our findings that African American men with a history of cigarette smoking had lower IGF1 levels and a lower IGF1:IGFBP3 molar ratio are consistent with those of some previous studies,^{43,44} although not all studies have confirmed this association.^{26,29,45,46} The association between a higher BMI and higher IGFBP3 levels have also been reported by some,^{30,42,44} although others did not find this association.^{24,47} While the mechanisms underlying racial/ethnic differential effects of common environmental stressors such as a large BMI and cigarette smoking are still under investigation, if confirmed by other studies, our findings will contribute to our understanding of chronic disease risk involving IGF signaling in African Americans.

A limitation of the analyses was that while our sample size was adequate to assess the independent effects of the factors under investigation, it was inadequate to evaluate the interaction between genetic factors and demographic and lifestyle factors on serum IGFBP3 or IGF1. However, a larger, more recently published study reported no interaction effect between the *IGFBP3 -202A* variant and lifestyle factors.⁴⁰ Another limitation is the low (53%) response rate, potentially raising concerns about the generalizability of findings to the general population. However, the main reason for nonresponse was failure to contact following identification by clinic registries—a reason unlikely to be related to serum IGF1 or IGFBP3 or factors assessed in our analyses.

In summary, commonly identified risk factors for chronic diseases, including a history of cigarette smoking, a large BMI, and carrying at least 1 *IGF1 (CA)₁₉* repeat allele predicted variation in serum IGF1 and IGFBP3 levels in African American men but not white men. These findings suggest that while variations in serum IGFs are clearly regulated by endogenous complex physiologic systems, some lifestyle and genetic variants appear to operate differently depending on race/ethnicity. If confirmed in larger studies, our observations will contribute to a more detailed understanding of ethnicity/race-specific insulinlike growth factor–signaling pathway, which should guide public health and therapeutic interventions.

ACKNOWLEDGMENTS

We thank Alice Neary, RN; Mary Beth Bell, MPH; Kymberly Gorham; and Regina Whitaker for assistance with data collection and laboratory analyses.

REFERENCES

1. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? *Cancer Causes Control*. 1996;7:605-625.
2. Kaaks R. The epidemiology of diet and colorectal cancer: review and perspectives for future research using biological markers. *Annali dell'Istituto*

superiore di sanita. 1996;32:111-121.

3. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. *Diabetes*. 2001;50(3):637-642.
4. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst*. 1998;90(17):1292-1299.
5. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2002;11(12):1566-1573.
6. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. *J Natl Cancer Inst*. 2000;92(18):1472-1489.
7. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. *J Natl Cancer Inst*. 1999;91(7):620-625.
8. Manousos O, Souglakos J, Bosetti C, et al. IGF-I and IGF-II in relation to colorectal cancer. *Int J Cancer*. 1999;83(1):15-17.
9. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. *J Natl Cancer Inst*. 2002;94(14):1099-1106.
10. Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. *Cancer Epidemiol Biomarkers Prev*. 2001;10(5):421-427.
11. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. *J Clin Endocrinol Metab*. 2000;85(11):4258-4265.
12. Leitzmann MF. Is there a link between macronutrient intake and prostate cancer? *Nat Clin Pract Oncol*. 2005;2(4):184-185.
13. Li L, Yu H, Schumacher F, Casey G, Witte JS. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). *Cancer Causes Control*. 2003;14(8):721-726.
14. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. *Br J Cancer*. 1997;76(9):1115-1118.
15. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. *Cancer Causes Control*. 2005;16(3):255-262.
16. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. *Br J Cancer*. 2001;85(7):991-996.
17. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. *J Natl Cancer Inst*. 2000;92(23):1910-1917.
18. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. *J Natl Cancer Inst*. 1998;90(12):911-915.
19. Jones JJ, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. *Endocr Rev*. 1995;16(1):3-34.
20. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. *Horm Metab Res*. 2003;35(11-12):726-733.
21. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. *Cancer*. 2005;103(1):76-84.
22. Lopez J.B. RMS, L.P. Chin. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer? *Int J Biol Markers*. 2004;19:164-167.
23. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. *J Clin Oncol*. 2002;20(3):833-841.
24. Chang S, Wu X, Yu H, Spitz MR. Plasma concentrations of insulin-like growth factors among health adult men and postmenopausal women: Associations with body composition, lifestyle and reproductive factors. *Cancer Epidemiol Biomarkers Prev*. 2002;11:768-766.

25. Gapstur SM, Kopp P, Chiu BC, Gann PH, Colangelo LA, Liu K. Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in Black and White men: the CARDIA Male Hormone Study. *Cancer Epidemiol Biomarkers Prev.* 2004;13(12):2208-2216.
26. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. *Am J Epidemiol.* 1997;145(11):970-976.
27. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. *Cancer Epidemiol Biomarkers Prev.* 2005;14(6):1394-1401.
28. Barrett-Connor E, Goodman-Gruen D. Gender differences in insulin-like growth factor and bone mineral density association in old age: the Rancho Bernardo Study. *J Bone Miner Res.* 1998;13(8):1343-1349.
29. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C. Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. *J Clin Oncol.* 1999;17(3):813-817.
30. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. *Cancer Epidemiol Biomarkers Prev.* 2004;13(9):1444-1451.
31. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2001;10(4):377-384.
32. Probst-Hensch NM, Wang H, Goh VH, Seow A, Lee HP, Yu MC. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. *Cancer Epidemiol Biomarkers Prev.* 2003;12(8):739-746.
33. Wright N.M. NP, S. Willi, et al. Demonstration of a lack of racial difference in secretion of growth hormone despite a racial difference in bone mineral density in premenopausal women—a Clinical Research Center study. *J Clin. Endocrinol. Metab.* 1996;81:1023-1026.
34. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. *J Clin Endocrinol Metab.* 2001;86(3):1274-1280.
35. Rietveld I, Janssen JA, van Rossum EF, et al. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. *Clin Endocrinol (Oxf).* 2004;61(2):195-203.
36. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. *J Clin Endocrinol Metab.* 1998;83(7):2286-2290.
37. Schildkraut JM, Demark-Wahnefried W, Wenham RM, et al. IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. *Cancer Epidemiol Biomarkers Prev.* 2005;14(2):403-408.
38. Hoyo C, Grubber J, Demark-Wahnefried W, et al. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. *J Natl Med Assoc.* 2007;99(7):718-722.
39. Cheng I, DeLellis Henderson K, Haiman CA, et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. *J Clin Endocrinol Metab.* 2007;92(9):3660-3666.
40. McGreevy KM, Hoel BD, Lipsitz SR, Hoel DG. Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males. *Public Health Nutr.* 2007;10(1):97-105.
41. Maskarinec G, Takata Y, Murphy SP, Franke AA, Kaaks R. Insulin-like growth factor-1 and binding protein-3 in a 2-year soya intervention among premenopausal women. *Br J Nutr.* 2005;94(3):362-367.
42. Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ. Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. *Cancer Causes Control.* 2003;14(1):65-74.
43. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. *Clin Endocrinol (Oxf).* 1994;41(3):351-357.
44. Teramukai S, Rohan T, Lee KY, Eguchi H, Oda T, Kono S. Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men. *Jpn J Cancer Res.* 2002;93(11):1187-1194.
45. Lukanova A, Toniolo P, Akhmedkhanov A, et al. A cross-sectional study of IGF-I determinants in women. *Eur J Cancer Prev.* 2001;10(5):443-452.
46. Signorello LB, Adami HO. Prostate Cancer. In: Adami H-O HD, Trichopoulos D, ed. *Textbook of Cancer Epidemiology.* Vol 1. New York: Oxford University Press; 2002:599.
47. Akanji AO, Suresh CG, Al-Radwan R, Fatania HR. Insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein (IGFBP)-3 levels in Arab subjects with coronary heart disease. *Scand J Clin Lab Invest.* 2007;67(5):553-559. ■